When many people look at Moderna today, their first reaction is still:
“The COVID vaccine company.”
And this has been one of Moderna’s biggest challenges over the past few years.
During the pandemic, the company generated significant revenue from its COVID vaccine.
However, after the peak of the pandemic passed, COVID vaccine demand declined, and Moderna’s revenue fell substantially.
Therefore, the market has continued asking:
“Beyond COVID vaccines, what else does Moderna have?”
By September 18, 2026, this question had begun to receive a clearer answer than before.
Because Moderna is attempting to transform from:
“A company that generated revenue from one COVID vaccine”
into:
“An mRNA platform company with respiratory vaccines, cancer therapies, and rare disease treatments.”
This is the most important investment logic when analyzing MRNA on September 18.
First, the Reality: Moderna Has Not Yet Returned to High Revenue Levels
In Q2 2026, Moderna generated total revenue of:
$145 million.
Compared with:
$142 million in the same period last year.
There was essentially no meaningful growth.
GAAP net loss was approximately:
$800 million.
Diluted loss per share was:
$1.97.
Compared with:
$2.13 per share loss in the same period last year.
Therefore, based only on current financial statements, Moderna is not a company with:
Rapid revenue growth and continuously rising profits.
Quite the opposite.
The company remains in a very typical:
Product transition phase.
The previous growth engine, COVID vaccines, can no longer support its former revenue scale.
Meanwhile, new products have not yet fully reached commercial scale.
Therefore, the most important question for MRNA today is not:
“How much money will the company make this year?”
The more important question is:
“Can the company’s product pipeline truly replace the previous revenue engine over the next two to three years?”
This Is Also the Biggest Difference Between Biotechnology Companies and Traditional Technology Companies
When analyzing NVIDIA, investors can focus on:
Revenue.
Gross margin.
Orders.
Data center investment.
When analyzing Meta, investors can focus on:
Users.
Advertising revenue.
Cash flow.
But biotechnology companies like Moderna cannot be analyzed only by looking at next quarter’s revenue.
Because the value of a biotechnology company often comes from:
Products that do not yet generate revenue today.
A drug in clinical development may generate:
$0 revenue.
But if it succeeds in Phase 3 trials and receives regulatory approval, its commercial value can change dramatically.
Therefore, the most important thing to evaluate with MRNA is:
Pipeline.
On August 5, Moderna Crossed an Important Milestone
The U.S. FDA officially approved:
mFLUSIVA (mRNA-1010)
for the prevention of influenza in adults aged 50 and older.
The approval included:
Traditional approval for adults aged 50–64.
Accelerated approval for adults aged 65 and older, requiring additional studies to confirm clinical benefit.
This became Moderna’s:
Fifth globally approved product
and:
The first FDA-approved mRNA influenza vaccine.
The importance of this milestone is not simply:
“Moderna added another vaccine.”
The deeper significance is:
It demonstrated that the mRNA platform could expand beyond COVID into another major respiratory disease area.
Why Is mFLUSIVA Worth Watching?
Traditional influenza vaccines have existed for many years.
Therefore, Moderna is not entering a market without competition.
Companies including:
Sanofi,
GSK,
and CSL
already have established influenza vaccine products.
The key question is:
Can an mRNA influenza vaccine provide meaningful advantages?
According to FDA materials, in a Phase 3 study involving more than:
40,000 adults aged 50 and older,
mFLUSIVA demonstrated a relative vaccine effectiveness of:
26.6%
compared with a standard-dose influenza vaccine.
The FDA also noted that no serious vaccine-related safety signals were identified in the relevant studies, although reactogenicity was higher than the comparator vaccine and was generally mild to moderate and temporary.
Simply put:
Moderna has taken mRNA technology from its COVID success and successfully extended it into influenza.
For the long-term value of the platform, this is an important validation.
However, the Event That Truly Changed the Moderna Story Happened on August 19
Moderna and Merck jointly announced that:
The personalized cancer therapy:
Intismeran autogene (V940 / mRNA-4157)
combined with Merck’s:
KEYTRUDA (pembrolizumab)
achieved:
The primary endpoint of RFS — recurrence-free survival
and the key secondary endpoint:
DMFS — distant metastasis-free survival
in the Phase 3:
INTerpath-001 trial.
The companies stated that, compared with KEYTRUDA alone, the combination treatment achieved statistically significant and clinically meaningful improvements in both endpoints.
For Moderna, this announcement was far more important than a typical quarterly earnings report.
Why?
Because it caused the market to seriously reconsider a fundamental question:
Can mRNA technology be used for cancer treatment?
Historically, most people understood mRNA through vaccines.
The logic was:
Deliver a piece of mRNA into the human body.
Allow cells to produce a specific antigen.
Train the immune system to recognize that antigen.
Intismeran pushes this concept further.
Instead of producing the exact same treatment for every patient, it uses a different approach:
First, analyze each patient’s individual tumor.
Identify the unique mutations found in that patient’s cancer.
Then design:
A personalized mRNA therapy
based on those mutations.
The goal is to train the patient’s own immune system to:
Recognize and attack cancer cells specific to that individual patient.
This Is Completely Different From the Traditional “One Drug for Everyone” Model
Traditional medicines are more like:
Create a standard key first, then find the locks that fit that key.
The Intismeran approach is closer to:
Examine each patient’s lock first, then create a key specifically for that patient.
This is known as:
Individualized Neoantigen Therapy.
If this approach can eventually become commercially successful, its importance for Moderna would not simply be:
Selling another cancer drug.
It would demonstrate that the mRNA platform could expand into:
Personalized cancer treatment.
More Importantly, This Was Not an Early-Stage Clinical Result
One of the biggest challenges in biotechnology is:
Phase 1 looks promising.
Phase 2 looks promising.
Then Phase 3 fails.
Therefore, early-stage results cannot automatically be considered commercial success.
However, Intismeran achieved an important milestone:
Phase 3 success.
INTerpath-001 is a Phase 3 study involving patients with:
Stage IIB–IV high-risk melanoma
who had undergone complete surgical removal of their tumors.
Moderna and Merck stated that, in this adjuvant treatment setting, the combination therapy achieved statistically significant and clinically meaningful improvements in both:
RFS
and:
DMFS
compared with KEYTRUDA monotherapy.
This means the program moved another important step closer toward potential regulatory submission.
And Moderna Is Not Pursuing This Alone
The collaboration partner is:
Merck.
And the combination therapy uses:
KEYTRUDA.
KEYTRUDA is already one of the world’s most important cancer immunotherapies.
Therefore, the significance of this collaboration comes from the complementary roles of both companies.
Moderna provides:
Personalized mRNA cancer therapy.
Merck provides:
A mature PD-1 immune checkpoint inhibitor.
The combined mechanism is:
One therapy tells the immune system:
“This is what the cancer looks like.”
The other:
Removes a brake that prevents the immune system from attacking cancer cells.
Together, these two approaches create a potentially complementary treatment strategy.
Before the Phase 3 Results, Long-Term Phase 2 Data Had Already Provided Early Signals
In 2026, updated five-year follow-up data from KEYNOTE-942 further evaluated Intismeran combined with pembrolizumab in high-risk melanoma patients.
The relevant research was published online in June 2026 and entered the formal journal version of:
The Journal of Clinical Oncology
in September.
Therefore, the Phase 3 success announced on August 19 did not appear completely unexpected.
Before that announcement, the market had already seen:
Long-term Phase 2 follow-up results
and:
Progression into Phase 3 development.
The major change was:
The Phase 3 trial successfully achieved its primary endpoint.
For biotechnology assets, this represented an important change in the risk profile.
This Is Why MRNA on September 18 Could No Longer Be Viewed Simply as a “Vaccine Stock”
At this point, Moderna’s business story can be divided into at least three major areas.
The first:
Respiratory vaccines.
Including:
COVID,
RSV,
and influenza.
The second:
Cancer treatment.
With Intismeran as the core program.
The third:
Rare diseases and other mRNA-based therapies.
This includes:
Propionic Acidemia (mRNA-3927)
and other therapeutic programs.
Moderna’s publicly disclosed pipeline continues to identify Intismeran and mRNA-3927 as key therapeutic programs.
If all three areas can eventually develop successfully, Moderna can truly demonstrate:
mRNA is not just a COVID technology.
It is:
A drug development platform.
The Difference Between These Two Concepts Is Extremely Significant
If Moderna were only a COVID vaccine company:
The valuation question would be relatively simple:
How much revenue can COVID vaccines generate in the future?
But if Moderna becomes an mRNA platform company:
The question changes into:
How many different medicines can this technology platform create?
Vaccines.
Cancer therapies.
Rare disease treatments.
Respiratory disease products.
And potentially other therapeutic areas.
The value of a platform biotechnology company usually does not depend on a single product.
Instead, it depends on:
Whether the same technology can continuously generate new products.
However, One Major Reality Has Not Changed: Cash Consumption
As of June 30, 2026, Moderna held:
$6.9 billion
in cash, cash equivalents, and investments.
At the end of March, the figure was:
$7.5 billion.
This means cash declined by approximately:
$600 million
in one quarter.
The company also made a payment of:
$950 million
in July related to previously announced litigation settlement obligations.
Therefore, although Moderna maintains a relatively strong cash position, it cannot spend indefinitely without discipline.
This is why cost management has become increasingly important.
The Positive Development Is That the Company Continues Reducing Expenses
Following the Q2 earnings report, Moderna improved its 2026 GAAP operating expense outlook by approximately:
$200 million.
The company also raised its expected year-end 2026 cash balance target to:
$4.7 billion–$5.2 billion.
At the same time, Moderna continued expecting 2026 revenue compared with 2025 to:
Increase by up to approximately 10%.
This means management is currently working on two priorities simultaneously:
Continue advancing late-stage clinical programs.
And:
Extend the company’s cash runway as much as possible.
For a biotechnology company undergoing transformation, this balance is extremely important.
Because What Moderna Needs Now Is Time for New Products to Take Over
The company’s problem is not a lack of technology.
The challenge is:
The time gap between declining legacy products and the commercialization of new products.
mFLUSIVA has received approval.
However, new products require time to achieve commercial adoption.
Intismeran has achieved Phase 3 success.
But the company still needs:
Complete data,
Regulatory discussions,
and potential final approval.
Rare disease programs also require further clinical validation.
Therefore, Moderna today can be compared to:
An old engine that has slowed down, while a new engine has started but has not yet reached full power.
This is why MRNA remains a highly volatile biotechnology company.
The Norovirus Program Also Shows That Not Every mRNA Project Will Succeed
On July 31, Moderna also announced a negative development.
The norovirus vaccine candidate:
mRNA-1403
did not meet the statistical criteria required for early success in a Phase 3 interim analysis.
The company therefore planned to add a new study cohort.
This development is important because it reminds investors:
“The mRNA platform works” does not mean “every mRNA medicine will succeed.”
Every disease.
Every biological target.
Every clinical program.
Still needs to prove its own effectiveness.
This Is the Biggest Difference Between Biotechnology Investing and Other Industries
If NVIDIA’s new GPU does not perform as expected, the company can improve the next generation.
If Meta’s AI feature does not work well, the company can update and improve it.
But drug development is completely different.
A major Phase 3 clinical trial can require:
Several years of work
and:
Hundreds of millions of dollars in investment.
If the trial fails, the value of the program can decline dramatically almost immediately.
Therefore, Moderna’s biggest risk is not:
“AI competition.”
It is:
Clinical development risk.
The Second Risk Is Regulatory Approval
Although mFLUSIVA received FDA approval, the structure of that approval also needs to be understood.
For adults aged:
50–64,
the vaccine received:
Traditional Approval.
For adults aged:
65 and older,
it received:
Accelerated Approval.
The FDA requires additional studies to further confirm clinical benefit in this age group.
Therefore, “FDA approved” does not mean that no further work is required.
Biotechnology analysis requires looking beyond headlines.
Investors must continue evaluating:
Approval scope.
Label requirements.
Post-approval studies.
Commercial performance.
The Third Risk Is Commercialization
A successful medicine and a profitable medicine are not the same thing.
mFLUSIVA is entering an established influenza vaccine market.
There are already major competitors.
Therefore, future performance will depend on factors including:
Insurance coverage.
Physician adoption.
Distribution channels.
Pricing.
Market share.
And whether consumers choose an mRNA influenza vaccine.
Similarly, even if Intismeran eventually receives approval, it will remain a highly personalized therapy.
Each patient requires:
Tumor sequencing → Mutation identification → Personalized design → Manufacturing → Delivery.
This means the production and supply chain complexity may be significantly higher than traditional standardized medicines.
Therefore, after commercialization, new questions will emerge:
Can it be manufactured efficiently?
What will the cost structure look like?
How will hospitals integrate the treatment process?
These factors will become critical.
However, Moderna on September 18 Was Already Different From Earlier in the Year
At the beginning of the year, the market’s main question was:
“After COVID, can Moderna actually create anything else?”
By September 18, the company had at least two clearer answers.
The first:
mFLUSIVA.
It received FDA approval and demonstrated that mRNA technology could expand into seasonal influenza.
The second:
Intismeran.
It achieved key endpoints in a Phase 3 melanoma study, showing that mRNA technology may have potential beyond prevention and could enter cancer treatment.
Together, these two developments created a completely different picture.
Previously, Moderna’s biggest success came from:
Using mRNA to teach the human body to recognize a virus.
Now the company is attempting to prove something broader:
mRNA can help the immune system recognize influenza.
And even:
Help the immune system recognize cancer cells unique to each individual patient.
This is the real reason Moderna remains worth studying.
The Core Question for MRNA on September 18, 2026 Was No Longer About COVID Vaccine Sales
If investors only looked at today’s financial statements:
Revenue is low.
The company remains unprofitable.
Cash continues declining.
These are all real risks.
However, biotechnology companies are often valued based on:
Products that have not yet fully appeared in current revenue.
As of September 18, Moderna had developed a clearer path compared with several months earlier:
COVID / RSV
↓
mFLUSIVA entering influenza
↓
Intismeran entering cancer treatment
↓
mRNA-3927 and other programs exploring rare diseases
This is the true test of whether Moderna can become a platform company.
Therefore, the Key Question for MRNA on September 18, 2026 Was Not Simply “How Much Can COVID Vaccines Sell?”
The more important question was:
“Can Moderna prove that COVID was only the first successful product of the mRNA platform, rather than the only successful product?”
The approval of:
mFLUSIVA on August 5
moved this answer one step forward.
The Phase 3 success of:
Intismeran on August 19
represented an even more important milestone.
If Intismeran can successfully complete regulatory submission and eventually move toward commercialization, while influenza, RSV, and other pipeline programs gradually begin contributing revenue, then the market’s view of Moderna could shift from:
“A vaccine company whose pandemic-driven growth has ended”
toward:
“A biotechnology company with multiple commercial products and the ability to continuously create new medicines using the same mRNA platform.”
However, before this transformation is fully proven, four major factors still require continuous validation:
Clinical success rate.
Regulatory approval progress.
Commercialization capability.
Cash consumption management.
These four variables will determine whether Moderna can successfully complete its transition.
The Core Investment Logic of Moderna as of September 18, 2026
Moderna’s story is no longer simply about the past success of COVID vaccines.
The company is attempting to demonstrate that mRNA can become a broader pharmaceutical platform.
The potential development path is:
COVID vaccine success
↓
Expansion into respiratory vaccines
↓
Personalized cancer treatment
↓
Rare disease therapies
↓
A broader mRNA-based medicine platform
The important question is not whether Moderna already has a complete transformation.
It does not.
The important question is whether the company has created a credible path toward that transformation.
Final Perspective
A traditional vaccine company is usually evaluated by:
How many doses it can sell.
A platform biotechnology company is evaluated by:
How many products its technology platform can continue producing.
This is the fundamental difference.
As of:
September 18, 2026,
Moderna had not yet completed this transition.
However, the company had reached several important milestones:
mFLUSIVA demonstrated expansion of mRNA technology into influenza.
Intismeran Phase 3 results provided important validation for personalized cancer therapy.
mRNA-3927 and other programs continued representing future therapeutic opportunities.
At the same time:
Revenue remained under pressure.
Cash management remained important.
Clinical and regulatory risks continued.
Therefore, the central question for Moderna was:
Can the company transform the first major success of mRNA technology into a repeatable platform capable of creating multiple future medicines?
That is the key issue to monitor for MRNA after:
September 18, 2026.